Market Place
Sourcing Support
Adial Pharma Granted Patent for Alcohol & Drug Dependence Treatment
03 Dec 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Announces Positive AD04-103 Study Results
14 Nov 2024 //
GLOBENEWSWIRE
Adial Pharma Reports Q3 2024 Financial Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
Adial Pharma Appoints Vinay Shah as Chief Financial Officer
05 Nov 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
23 Oct 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Receives Patent Allowance For Genotype Combinations
17 Oct 2024 //
GLOBENEWSWIRE
Adial Pharma Commends Alcohol Abuse New Definition Of Recovery
15 Oct 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Announces Database Lock In AD04 Study
19 Sep 2024 //
GLOBENEWSWIRE
Adial To Present At H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Adial Pharma Signs Agreement With Boudicca Dx For AD04 Diagnostic Test
13 Aug 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Completes Dosing In AD04 Pharmacokinetics Study
07 Aug 2024 //
GLOBENEWSWIRE
Adial Files Patent To Extend Core Technology IP To 2044
31 Jul 2024 //
GLOBENEWSWIRE
Adial Advances To Second Cohort In AD04 Pharmacokinetics Study
23 Jul 2024 //
GLOBENEWSWIRE
Adial Pharma Announces Journal Publication Supporting AD04 For Alcohol Disorder
20 Jun 2024 //
GLOBENEWSWIRE
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
29 May 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports Q1 2024 Financials, Business Update
15 May 2024 //
GLOBENEWSWIRE
Adial Granted Key Patent From USPTO
22 Apr 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Highlights Safety Data of AD04 in Publication
10 Apr 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results
02 Apr 2024 //
GLOBENEWSWIRE
Adial Pharma Announces Exercise of Warrants for $3.5 Million Gross Proceeds
01 Mar 2024 //
GLOBENEWSWIRE
Adial Awarded New Patent from the United States Patent and Trademark Office
28 Feb 2024 //
GLOBENEWSWIRE
Adial to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
15 Feb 2024 //
ACCESSWIRE
Adial Awarded New Patent Notice of Allowance from the United States Patent
13 Feb 2024 //
GLOBENEWSWIRE
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
18 Jan 2024 //
GLOBENEWSWIRE
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
20 Dec 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
29 Nov 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Adial CMO and Key Opinion Leaders to Discuss New Aspects in Substance
31 Oct 2023 //
GLOBENEWSWIRE
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies
25 Oct 2023 //
GLOBENEWSWIRE
Adial Announces Closing of $4 Million Private Placement Priced At-The-Market
24 Oct 2023 //
GLOBENEWSWIRE
Adial Announces $4M Private Placement Priced At-The-Market Under Nasdaq Rules
20 Oct 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent
19 Oct 2023 //
GLOBENEWSWIRE
Adial to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th
19 Oct 2023 //
ACCESSWIRE
Adial Pharma Wins Frost & Sullivan`s 2023 North American Precision Medicine
18 Oct 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar
28 Sep 2023 //
GLOBENEWSWIRE
Adial to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders
28 Aug 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
23 Aug 2023 //
GLOBENEWSWIRE
Adial Reports Second Quarter 2023 Financial Results and Provides Business Update
21 Aug 2023 //
GLOBENEWSWIRE
Adial Provides Business Update Following Favorable Comments from US
11 Jul 2023 //
GLOBENEWSWIRE
Adial to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
01 Jun 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Adial Pharma Receives Notice of Exercise from Adovate for the Acquisition
10 May 2023 //
GLOBENEWSWIRE
Adial Reports 2022 Fiscal Year Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Adial Engages The Keswick Group to Advance Activities for Development of AD04
21 Mar 2023 //
GLOBENEWSWIRE
Adial Provides Update on Regulatory Strategy for AD04
06 Mar 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Schedules Business Update Conference Call
02 Mar 2023 //
GLOBENEWSWIRE
Adial Announces Closing of $0.75M At-The-Market Registered Direct Offering
27 Feb 2023 //
GLOBENEWSWIRE
Adial Announces Pricing of $0.75M At-The-Market Registered Direct Offering
24 Feb 2023 //
GLOBENEWSWIRE
Adial Confirms Scheduling of Meetings with FDA & EU Agencies for AD04
21 Feb 2023 //
GLOBENEWSWIRE
Adial Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
01 Feb 2023 //
GLOBENEWSWIRE
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030
26 Sep 2022 //
GLOBENEWSWIRE
Adial Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005
06 Sep 2022 //
GLOBENEWSWIRE
Adial Pharmaceuticals Reports Second Quarter 2022 Financial Results
16 Aug 2022 //
GLOBENEWSWIRE
Adial at a fork in the road with AUD med after phase 3 flunk
21 Jul 2022 //
FIERCEBIOTECH
Adial Pharma to Announce Topline Results of ONWARD PIII Trial for AD04
18 Jul 2022 //
GLOBENEWSWIRE
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
28 Jun 2022 //
GLOBENEWSWIRE
Adial Pharmaceuticals Announces Database Lock for the ONWARD PIII Trial
27 Jun 2022 //
GLOBENEWSWIRE
